
Shares of drugmaker TG Therapeutics TGTX.O up about 10% at $30.64 premarket
TGTX expects total revenue for 2026 in the range of $875 million to $900 million, compared with estimates of $895.63 million, according to data compiled by LSEG
Expects total revenue for 2025 at $616 million, above analysts' estimates of $606.6 million
TGTX expects 2025 U.S. sales of $594 million for its multiple sclerosis drug, Briumvi, up about 92% from a year earlier
Jefferies analysts expect data for subcutaneous version of Briumvi, which is expected by the end of 2026, to be "a large inflection point"
Shares fell marginally in 2025